Drawing for YUMAB

USPTO serial 79191669

YUMAB

Reviewed by CopyMark Law Group

Reg. 5238680Status 739Renewal
Filing date
Status date
Registration date
Jul 11, 2017
Examiner
SHANAHAN, PATRICK
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with YUMAB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $1,950

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joseph V. Norvell

Joseph V. Norvell Norvell IP, llcP.O. Box 2461Chicago, IL 60690United States

Goods and services

ClassDescriptionStatusFirst use
001[ Monoclonal antibodies for quantitative determination of leukocyte subsets other than for medical purposes; chemicals components being biochemicals for producing radio-labelled monoclonal antibodies for industrial or scientific purposes; proteins for detecting antibodies other than for medical purposes; ] monoclonal antibodies for industrial use; monoclonal antibody reagents, other than for medical use; antigens and antibodies being biochemicals for diagnostic use not for medical purposes; immunological antibodies, being biochemicals, other than for medical use; tagged antibodies being biochemicals for scientific use; [ monoclonal antibodies for qualitative determination of leukocyte subsets other than for medical purposes; linkage compounds being biochemicals for scientific purposes for coupling of radioactive compounds to antibodies; reagents for use in the development of hybridoma antibodies other than for medical or veterinary purposes; ] biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; proteins for binding antibodies other than for medical purposes; monoclonal antibodies for scientific use; [ linkage compounds being biochemicals for scientific purposes for coupling antibodies to radio nuclides; monoclonal antibodies for research into haematopoietic systems other than for medical purposes; ] reagents for use in development of monoclonal antibodies other than for medical or veterinary purposes; [ components for producing radio-labelled antibody fragments for industrial or scientific purposes being biochemicals; ] tagged antibodies being biochemicals for laboratory use; reagents in kit form for conducting enzyme-linked immunosorbent assays (elisa) other than for medical or veterinary purposes comprised primarily of biochemicalsACTIVE—
005Antibodies, antibody fragments and antigens in the nature of pharmaceuticals for the treatment of cancer, haematopoietic diseases, autoimmune diseases, neurodegenerative diseases, metabolic diseases, eye diseases, infections, diseases of heart and circulation, bone diseases, transplantation, sepsis, intoxications, and adverse drug reactionsACTIVE—
042Scientific research; technological services being antibody engineering and design; industrial analysis and research services in the nature of laboratory research and new product design services relating to the production of monoclonal antibodiesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 11, 2026REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Apr 30, 2026RNWLINTERNATIONAL REGISTRATION RENEWED—
Feb 8, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jan 15, 2025XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Jan 15, 2025XXCRGENERIC MADRID TRANSACTION CREATED—
Dec 4, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 27, 2024NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Sep 27, 2024C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Sep 17, 2024EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Apr 3, 2024PR75POST REGISTRATION ACTION MAILED - SEC. 71 & 15—
Mar 25, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 10, 2023ES75TEAS SECTION 71 & 15 RECEIVED—
Feb 18, 2023NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 15, 2019ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Nov 10, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 20, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 20, 2017FIMPFINAL DISPOSITION PROCESSED—
Oct 11, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 11, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 25, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 22, 2017GPNXNOTIFICATION PROCESSED BY IB—
Apr 21, 2017DOCKASSIGNED TO EXAMINER—
Apr 5, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 5, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Apr 5, 2017NPUBNOTICE OF PUBLICATION—
Mar 20, 2017CNEAEXAMINERS AMENDMENT MAILED—
Mar 18, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 18, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Mar 18, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 16, 2016RFNTREFUSAL PROCESSED BY IB—
Sep 28, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 28, 2016RFRRREFUSAL PROCESSED BY MPU—
Sep 27, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 26, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 20, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 16, 2016DOCKASSIGNED TO EXAMINER—
Sep 16, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 15, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance